Your browser doesn't support javascript.
loading
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
Larkin, James; Del Vecchio, Michele; Mandalá, Mario; Gogas, Helen; Arance Fernandez, Ana M; Dalle, Stéphane; Cowey, Charles Lance; Schenker, Michael; Grob, Jean-Jacques; Chiarion-Sileni, Vanna; Marquez-Rodas, Ivan; Butler, Marcus O; Di Giacomo, Anna Maria; Middleton, Mark R; Lutzky, Jose; de la Cruz-Merino, Luis; Arenberger, Petr; Atkinson, Victoria; Hill, Andrew G; Fecher, Leslie A; Millward, Michael; Nathan, Paul D; Khushalani, Nikhil I; Queirolo, Paola; Ritchings, Corey; Lobo, Maurice; Askelson, Margarita; Tang, Hao; Dolfi, Sonia; Ascierto, Paolo A; Weber, Jeffrey.
Afiliación
  • Larkin J; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Del Vecchio M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Mandalá M; Papa Giovanni XIII Hospital, Bergamo, Italy.
  • Gogas H; National and Kapodistrian University of Athens, Athens, Greece.
  • Arance Fernandez AM; Hospital Clínic de Barcelona, Barcelona, Spain.
  • Dalle S; Hospices Civils de Lyon, Pierre Bénite, France.
  • Cowey CL; Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas.
  • Schenker M; Oncology Center Sf Nectarie Ltd., Craiova, Romania.
  • Grob JJ; Aix Marseille University, Hôpital de la Timone, Marseille, France.
  • Chiarion-Sileni V; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Marquez-Rodas I; General University Hospital Gregorio Marañón and CIBERONC, Madrid, Spain.
  • Butler MO; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Di Giacomo AM; Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy.
  • Middleton MR; Churchill Hospital, Oxford, United Kingdom.
  • Lutzky J; Sylvester Comprehensive Cancer Center, Miami, Florida.
  • de la Cruz-Merino L; Hospital Universitario Virgen Macarena, Clinical Oncology Department, University of Seville, Seville, Spain.
  • Arenberger P; Charles University Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
  • Atkinson V; Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Greenslopes, Queensland, Australia.
  • Hill AG; Tasman Health Care, Southport, QLD, Australia.
  • Fecher LA; University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.
  • Millward M; University of Western Australia and Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.
  • Nathan PD; Mount Vernon Hospital, Middlesex, United Kingdom.
  • Khushalani NI; H. Lee Moffitt Cancer Center, Tampa, Florida.
  • Queirolo P; IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Ritchings C; Bristol Myers Squibb, Princeton, New Jersey.
  • Lobo M; Bristol Myers Squibb, Princeton, New Jersey.
  • Askelson M; Bristol Myers Squibb, Princeton, New Jersey.
  • Tang H; Bristol Myers Squibb, Princeton, New Jersey.
  • Dolfi S; Bristol Myers Squibb, Princeton, New Jersey.
  • Ascierto PA; Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.
  • Weber J; Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York.
Clin Cancer Res ; 29(17): 3352-3361, 2023 09 01.
Article en En | MEDLINE | ID: mdl-37058595

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nivolumab / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Nivolumab / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos